Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future

The Lancet

Volumn 383, Issue 9922, 2014, Pages 1068-1083

  Kahn, Steven E ^a,d   Cooper, Mark E ^b   Del Prato, Stefano ^c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c UNIVERSITY OF PISA   (Italy)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; NATEGLINIDE; PLACEBO; PRAMLINTIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TETRAHYDROLIPSTATIN; TROGLITAZONE; UNINDEXED DRUG; VILDAGLIPTIN; ACARBOSE; ALOGLIPTIN; BROMOCRIPTINE; COLESEVELAM; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; LINAGLIPTIN; MIGLITOL; PIOGLITAZONE; REPAGLINIDE; SAXAGLIPTIN; VOGLIBOSE;

BARIATRIC SURGERY; CALORIC INTAKE; CARDIOVASCULAR RISK; CELL FUNCTION; ENERGY EXPENDITURE; ENVIRONMENTAL CHANGE; EPIGENETICS; FEEDBACK SYSTEM; GENETICS; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HISTORY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN TREATMENT; LIFESTYLE MODIFICATION; MICROBIOME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; REVIEW; ARTICLE; BRAIN; CELL COUNT; CLINICAL TRIAL (TOPIC); CONCENTRATION (PARAMETERS); GLUCOSE HOMEOSTASIS; HEREDITY; HYPERGLYCEMIA; INFLAMMATION; INSULIN SENSITIVITY; INTESTINE; PANCREAS ISLET ALPHA CELL; PATHOGENESIS;

BARIATRIC SURGERY; DIABETES MELLITUS, TYPE 2; EPIGENESIS, GENETIC; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; GLUCAGON-SECRETING CELLS; GLUCOSE; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; OBESITY;

EID: 84896495719     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62154-6     Document Type: Review

References (202)

1. International Diabetes Federation. IDF Diabetes Atlas, update 2012 5th edn. http://www.idf.org/diabetesatlas/5e/Update2012 (accessed April 4, 2013)
2. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest 1960; 39: 1157-75
3. Perley M, Kipnis DM. Plasma insulin responses to glucose and tolbutamide of normal weight and obese diabetic and nondiabetic subjects. Diabetes 1966; 15: 867-74
4. Himsworth HP. Diabetes mellitus: its diff erentiation into insulinsensitive and insulin-insensitive types. Lancet 1936; 227: 127-30
5. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607
6. Cnop M, Landchild MJ, Vidal J, et al. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 2002; 51: 1005-15
7. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantifi cation of the relationship between insulin sensitivity and ß-cell function in human subjects: evidence for a hyperbolic function. Diabetes 1993; 42: 1663-72
8. Genuth S, Alberti KG, Bennett P, et al, and the Expert Committee on the Diagnosis and Classifi cation of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-67
9. Stancakova A, Javorsky M, Kuulasmaa T, Haff ner SM, Kuusisto J, Laakso M. Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men Diabetes 2009; 58: 1212-21
10. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-94
11. Kahn SE, Lachin JM, Zinman B, et al, and the ADOPT Study Group Effects of rosiglitazone, glyburide, and metformin on ß-cell function and insulin sensitivity in ADOPT. Diabetes 2011; 60: 1552-60
12. Cnop M, Vidal J, Hull RL, et al. Progressive loss of ß-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 2007; 30: 677-82
13. Ward WK, Johnston CLW, Beard JC, Benedetti TJ, Halter JB, Porte D Jr. Insulin resistance and impaired insulin secretion in subjects with histories of gestational diabetes mellitus. Diabetes 1985; 34: 861-69
14. Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome J Clin Endocrinol Metab 1996; 81: 942-47
15. Kahn SE, Larson VG, Schwartz RS, et al. Exercise training delineates the importance of B-cell dysfunction to the glucose intolerance of human aging. J Clin Endocrinol Metab 1992; 74: 1336-42
16. Elbein SC, Hasstedt SJ, Wegner K, Kahn SE. Heritability of pancreatic beta-cell function among nondiabetic members of Caucasian familial type 2 diabetic kindreds. J Clin Endocrinol Metab 1999; 84: 1398-403
17. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE, and the American Diabetes Association GENNID Study Group. Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the U.S. Diabetes 2002; 51: 2170-78
18. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPAR?2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 284-87
19. Morris AP, Voight BF, Teslovich TM, et al, and the Wellcome Trust Case Control Consortium, the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators, the Genetic Investigation of ANthropometric Traits (GIANT) Consortium, the Asian Genetic Epidemiology Network-Type 2 Diabetes (AGEN-T2D) Consortium, the South Asian Type 2 Diabetes (SAT2D) Consortium, and the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 2012; 44: 981-90
20. Scott RA, Lagou V, Welch RP, et al, and the DIAbetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium. Largescale association analyses identify new loci infl uencing glycemic traits and provide insight into the underlying biological pathways Nat Genet 2012; 44: 991-1005
21. McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med 2010; 363: 2339-50
22. Meigs JB, Shrader P, Sullivan LM, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes N Engl J Med 2008; 359: 2208-19
23. Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008; 359: 2220-32
24. Hu FB, van Dam RM, Liu S. Diet and risk of type II diabetes: the role of types of fat and carbohydrate. Diabetologia 2001; 44: 805-17
25. Chen M, Bergman RN, Porte D Jr. Insulin resistance and ß-cell dysfunction in aging: the importance of dietary carbohydrate J Clin Endocrinol Metab 1988; 67: 951-57
26. Guenard F, Deshaies Y, Cianflone K, Kral JG, Marceau P, Vohl M-C Differential methylation in glucoregulatory genes of off spring born before vs. after maternal gastrointestinal bypass surgery Proc Natl Acad Sci USA 2013; 110: 11439-44
27. Thayer KA, Heindel JJ, Bucher JR, Gallo MA. Role of environmental chemicals in diabetes and obesity: a National Toxicology Program workshop review. Environ Health Perspect 2012; 120: 779-89
28. Opie EL. The relation of diabetes mellitus to lesions of the pancreas: hyaline degeneration of the islets of Langerhans. J Exp Med 1901; 5: 527-40
29. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC ß-cell defi cit and increased ß-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-10
30. Rahier J, Guiot Y, Goebbels RM, Sempoux C, Henquin JC Pancreatic ß-cell mass in European subjects with type 2 diabetes Diabetes Obes Metab 2008; 10 (suppl 4): 32-42
31. Jurgens CA, Toukatly MN, Fligner CL, et al. ß-cell loss and ß-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition. Am J Pathol 2011; 178: 2632-40
32. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and ß-cell dysfunction. Endocr Rev 2008; 29: 351-66
33. Perl S, Kushner JA, Buchholz BA, et al. Significant human ß-cell turnover is limited to the first three decades of life as determined by in vivo thymidine analog incorporation and radiocarbon dating J Clin Endocrinol Metab 2010; 95: E234-39
34. Dunning BE, Gerich JE. The role of α-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007; 28: 253-83
35. Stagner JI, Samols E. The vascular order of islet cellular perfusion in the human pancreas. Diabetes 1992; 41: 93-97
36. Gromada J, Franklin I, Wollheim CB. α-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 2007; 28: 84-116
37. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-65
38. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011; 54: 10-18
39. Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA Diff erential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care 2003; 26: 791-98
40. Ward WK, Beard JC, Halter JB, Pfeifer MA, Porte D Jr Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes Care 1984; 7: 491-502
41. Stefater MA, Wilson-Perez HE, Chambers AP, Sandoval DA, Seeley RJ. All bariatric surgeries are not created equal: insights from mechanistic comparisons. Endocr Rev 2012; 33: 595-622
42. Saeidi N, Meoli L, Nestoridi E, et al. Reprogramming of intestinal glucose metabolism and glycemic control in rats after gastric bypass. Science 2013; 341: 406-10
43. Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev 2012; 26: 312-24
44. Pols TW, Noriega LG, Nomura M, Auwerx J, Schoonjans K. The bile acid membrane receptor TGR5: a valuable metabolic target. Dig Dis 2011; 29: 37-44
45. Meyer-Gerspach AC, Steinert RE, Keller S, Malarski A, Schulte FH, Beglinger C. Effects of chenodeoxycholic acid on the secretion of gut peptides and fi broblast growth factors in healthy humans J Clin Endocrinol Metab 2013; 98: 3351-58
46. Diamant M, Blaak EE, de Vos WM. Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? Obes Rev 2011; 12: 272-81
47. Kootte RS, Vrieze A, Holleman F, et al. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes Metab 2012; 14: 112-20
48. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012; 490: 55-60
49. Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013; 498: 99-103
50. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913-16 e7
51. Jumpertz R, Le DS, Turnbaugh PJ, et al. Energy-balance studies reveal associations between gut microbes, caloric load, and nutrient absorption in humans. Am J Clin Nutr 2011; 94: 58-65
52. Porte D Jr. Sympathetic regulation of insulin secretion: its relation to diabetes mellitus. Arch Intern Med 1969; 123: 252-60
53. Nonogaki K. New insights into sympathetic regulation of glucose and fat metabolism. Diabetologia 2000; 43: 533-49
54. Miller RE. Pancreatic neuroendocrinology: peripheral neural mechanisms in the regulation of the Islets of Langerhans Endocr Rev 1981; 2: 471-94
55. Berthoud HR, Jeanrenaud B. Acute hyperinsulinemia and its reversal by vagotomy after lesions of the ventromedial hypothalamus in anesthetized rats. Endocrinology 1979; 105: 146-51
56. Obici S, Zhang BB, Karkanias G, Rossetti L. Hypothalamic insulin signaling is required for inhibition of glucose production. Nat Med 2002; 8: 1376-82
57. Lam TK, Gutierrez-Juarez R, Pocai A, Rossetti L. Regulation of blood glucose by hypothalamic pyruvate metabolism. Science 2005; 309: 943-47
58. Lam TK, Pocai A, Gutierrez-Juarez R, et al. Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis Nat Med 2005; 11: 320-27
59. Schwartz MW, Figlewicz DP, Baskin DG, Woods SC, Porte D Jr Insulin in the brain: a hormonal regulator of energy balance Endocr Rev 1992; 13: 387-414
60. Thaler JP, Yi CX, Schur EA, et al. Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest 2012; 122: 153-62
61. Bass J, Takahashi JS. Circadian integration of metabolism and energetics. Science 2010; 330: 1349-54
62. Hanlon EC, Van Cauter E. Quantifi cation of sleep behavior and of its impact on the cross-talk between the brain and peripheral metabolism. Proc Natl Acad Sci USA 2011; 108 (suppl 3): 15609-16
63. Dula SB, Jecmenica M, Wu R, et al. Evidence that low-grade systemic inflammation can induce islet dysfunction as measured by impaired calcium handling. Cell Calcium 2010; 48: 133-42
64. Nicol LE, Grant WF, Comstock SM, et al. Pancreatic inflammation and increased islet macrophages in insulin-resistant juvenile primates. J Endocrinol 2013; 217: 207-13
65. Barbarroja N, Lopez-Pedrera C, Garrido-Sanchez L, et al Progression from high insulin resistance to type 2 diabetes does not entail additional visceral adipose tissue inflammation. PLoS One 2012; 7: e48155
66. Haffner S, Temprosa M, Crandall J, et al, and the Diabetes Prevention Program Research Group. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005; 54: 1566-72
67. Pfutzner A, Schondorf T, Hanefeld M, Forst T. High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone. J Diabetes Sci Tech 2010; 4: 706-16
68. Ridker PM, Howard CP, Walter V, et al, and the CANTOS Pilot Investigative Group. Effects of interleukin-1ß inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fi brinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012; 126: 2739-48
69. Cavelti-Weder C, Babians-Brunner A, Keller C, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012; 35: 1654-62
70. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009; 32: 1663-68
71. Donath MY, Storling J, Maedler K, Mandrup-Poulsen T Infl ammatory mediators and islet ß-cell failure: a link between type 1 and type 2 diabetes. J Mol Med (Berl) 2003; 81: 455-70
72. Boni-Schnetzler M, Boller S, Debray S, et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 2009; 150: 5218-29
73. Maedler K, Sergeev P, Ris F, et al. Glucose-induced ß cell production of IL-1ß contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-60
74. Dinarello CA. Reduction of inflammation by decreasing production of interleukin-1 or by specific receptor antagonism. Int J Tissue React 1992; 14: 65-75
75. Herder C, Brunner EJ, Rathmann W, et al. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care 2009; 32: 421-23
76. Luotola K, Pietila A, Zeller T, et al, and the Health 2000 and FINRISK97 Studies. Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levels and the development of type 2 diabetes. J Intern Med 2011; 269: 322-32
77. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117: 175-84
78. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91
79. Johnson AM, Olefsky JM. The origins and drivers of insulin resistance. Cell 2013; 152: 673-84
80. Gregor MF, Hotamisligil GS. Infl ammatory mechanisms in obesity Annu Rev Immunol 2011; 29: 415-45
81. Thaler JP, Schwartz MW. Minireview: inflammation and obesity pathogenesis: the hypothalamus heats up. Endocrinology 2010; 151: 4109-15
82. Ling C, Groop L. Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes 2009; 58: 2718-25
83. Keating ST, El-Osta A. Epigenetic changes in diabetes. Clin Genet 2013; 84: 1-10
84. Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that diff erentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009; 9: 311-26
85. Wurtz P, Makinen VP, Soininen P, et al. Metabolic signatures of insulin resistance in 7,098 young adults. Diabetes 2012; 61: 1372-80
86. Floegel A, Stefan N, Yu Z, et al. Identifi cation of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 2013; 62: 639-48
87. van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. α-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28: 154-63
88. Younk LM, Mikeladze M, Davis SN. Pramlintide and the treatment of diabetes: a review of the data since its introduction Expert Opin Pharmacother 2011; 12: 1439-51
89. Marina AL, Utzschneider KM, Wright LA, Montgomery BK, Marcovina SM, Kahn SE. Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and ß-cell function. Diabetes Care 2012; 35: 1119-25
90. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-705
91. Drucker DJ, Buse JB, Taylor K, et al, and the DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 2008; 372: 1240-50
92. Rachman J, Barrow BA, Levy JC, Turner RC. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM Diabetologia 1997; 40: 205-11
93. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and ß-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359: 824-30
94. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012; 33: 187-215
95. Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol 2013; 10: 73-84
96. Scirica BM, Bhatt DL, Braunwald E, et al, and the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-26
97. White WB, Cannon CP, Heller SR, et al, and the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-35
98. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009; 25: 1019-27
99. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33: 2349-54
100. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141: 150-56
101. Singh S, Chang H-Y, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med 2013; 173: 534-39
102. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013; 62: 2595-604
103. Kahn SE. Incretin therapy and islet pathology: a time for caution Diabetes 2013; 62: 2178-80
104. European Medicines Agency. Assessment report for GLP-1 based therapies. July 25, 2013. http://www.ema.europa.eu/docs/enGB/ documentlibrary/Report/2013/ 08/WC500147026.pdf (accessed Aug 1, 2013)
105. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications Diabet Med 2010; 27: 136-42
106. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011; 91: 733-94
107. Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 2012; 61: 2199-204
108. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159: 262-74
109. Lamos EM, Younk LM, Davis SN. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol 2013; 9: 763-75
110. Holt RI, Barnett AH, Bailey CJ. Bromocriptine: old drug, new formulation and new indication. Diabetes Obes Metab 2010; 12: 1048-57
111. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003; 289: 2254-64
112. Gorter KJ, van de Laar FA, Janssen PG, Houweling ST, Rutten GE Diabetes: glycaemic control in type 2 (drug treatments) Clin Evid (Online) 2012; 2012: 609
113. Garber AJ, King AB, Del Prato S, et al, and the NN1250-3582 (BEGIN BB T2D) Trial Investigators. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1498-507
114. Rosenstock J, Bergenstal RM, Blevins TC, et al. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care 2013; 36: 522-28
115. Ziesmer AE, Kelly KC, Guerra PA, George KG, Dunn FL. U500 regular insulin use in insulin-resistant type 2 diabetic veteran patients. Endocr Pract 2012; 18: 34-38
116. Siekmeier R, Scheuch G. Inhaled insulin-does it become reality? J Physiol Pharmacol 2008; 59 (suppl 6): 81-113
117. Card JW, Magnuson BA. A review of the efficacy and safety of nanoparticle-based oral insulin delivery systems Am J Physiol Gastrointest Liver Physiol 2011; 301: G956-67
118. Brownlee M, Cerami A. A glucose-controlled insulin-delivery system: semisynthetic insulin bound to lectin. Science 1979; 206: 1190-91
119. Bergenstal RM, Rosenstock J, Arakaki RF, et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012; 35: 2140-47
120. Burant CF, Viswanathan P, Marcinak J, et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2012; 379: 1403-11
121. Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-proteincoupled receptor FFAR2. Diabetes 2012; 61: 364-71
122. El Ouaamari A, Kawamori D, Dirice E, et al. Liver-derived systemic factors drive ß cell hyperplasia in insulin-resistant states. Cell Rep 2013; 3: 401-10
123. Yi P, Park JS, Melton DA. Betatrophin: a hormone that controls pancreatic ß cell proliferation. Cell 2013; 153: 747-58
124. Talchai C, Xuan S, Lin HV, Sussel L, Accili D. Pancreatic ß cell dediff erentiation as a mechanism of diabetic ß cell failure. Cell 2012; 150: 1223-34
125. Gelling RW, Du XQ, Dichmann DS, et al. Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA 2003; 100: 1438-43
126. Wynne K, Park AJ, Small CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) 2006; 30: 1729-36
127. Meininger GE, Scott R, Alba M, et al. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 2011; 34: 2560-66
128. Agius L. New hepatic targets for glycaemic control in diabetes Best Pract Res Clin Endocrinol Metab 2007; 21: 587-605
129. Conti R, Mannucci E, Pessotto P, et al. Selective reversible inhibition of liver carnitine palmitoyl-transferase 1 by teglicar reduces gluconeogenesis and improves glucose homeostasis Diabetes 2011; 60: 644-51
130. Alcain FJ, Villalba JM. Sirtuin activators. Expert Opin Ther Pat 2009; 19: 403-14
131. Ma YM, Tao RY, Liu Q, et al. PTP1B inhibitor improves both insulin resistance and lipid abnormalities in vivo and in vitro Mol Cell Biochem 2011; 357: 65-72
132. Kliewer SA, Mangelsdorf DJ. Fibroblast growth factor 21: from pharmacology to physiology. Am J Clin Nutr 2010; 91: 254S-57S
133. Adams AC, Halstead CA, Hansen BC, et al. LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys. PLoS One 2013; 8: e65763
134. Goldfine AB, Fonseca V, Jablonski KA, et al, and the Targeting Infl ammation Using Salsalate in Type 2 Diabetes Study Team Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2013; 159: 1-12
135. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-26
136. Tomlinson JW, Walker EA, Bujalska IJ, et al. 11ß-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004; 25: 831-66
137. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-70
138. Lindsay RS, Wake DJ, Nair S, et al. Subcutaneous adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metab 2003; 88: 2738-44
139. Goedecke JH, Wake DJ, Levitt NS, et al. Glucocorticoid metabolism within superfi cial subcutaneous rather than visceral adipose tissue is associated with features of the metabolic syndrome in South African women. Clin Endocrinol (Oxf) 2006; 65: 81-87
140. Gathercole LL, Lavery GG, Morgan SA, et al. 11ß-hydroxysteroid dehydrogenase 1: translational and therapeutic aspects. Endocr Rev 2013; 34: 525-55
141. Tschop MH, DiMarchi RD. Outstanding Scientifi c Achievement Award Lecture 2011: defeating diabesity: the case for personalized combinatorial therapies. Diabetes 2012; 61: 1309-14
142. Tan TM, Field BC, McCullough KA, et al. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia Diabetes 2013; 62: 1131-38
143. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53
144. Gerstein HC, Miller ME, Byington RP, et al, and the Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59
145. Duckworth W, Abraira C, Moritz T, et al, and the VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-39
146. Gerstein HC, Bosch J, Dagenais GR, et al, and the ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-28
147. Patel A, MacMahon S, Chalmers J, et al, and the ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72
148. Riddle MC, Ambrosius WT, Brillon DJ, et al, and the Action to Control Cardiovascular Risk in Diabetes Investigators Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010; 33: 983-90
149. Ismail-Beigi F, Craven T, Banerji MA, et al, and the ACCORD Trial Group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376: 419-30
150. Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia 2009; 52: 1699-708
151. Varewijck AJ, Yki-Jarvinen H, Schmidt R, Tennagels N, Janssen JA Concentrations of insulin glargine and its metabolites during longterm insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and IGF-I receptor signaling. Diabetes 2013; 62: 2539-44
152. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343: d4169
153. Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011; 343: d6898
154. Inzucchi SE, Bergenstal RM, Buse JB, et al, and the American Diabetes Association (ADA), and the European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-79
155. Gaede P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 2008; 358: 580-91
156. Wing RR, Bolin P, Brancati FL, et al, and the Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369: 145-54
157. Gregg EW, Chen H, Wagenknecht LE, et al, and the Look AHEAD Research Group. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 2012; 308: 2489-96
158. Wing RR, and the Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170: 1566-75
159. Foster GD, Borradaile KE, Sanders MH, et al, and the Sleep AHEAD Research Group of Look AHEAD Research Group. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med 2009; 169: 1619-26
160. Rejeski WJ, Ip EH, Bertoni AG, et al, and the Look AHEAD Research Group. Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med 2012; 366: 1209-17
161. Kahn SE, Haffner SM, Heise MA, et al, and the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43
162. Bunck MC, Corner A, Eliasson B, et al. Effects of exenatide on measures of ß-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011; 34: 2041-47
163. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537-44
164. Tuomilehto J, Lindstrom J, Eriksson JG, et al, and the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50
165. Knowler WC, Barrett-Connor E, Fowler SE, et al, and the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 2002; 346: 393-403
166. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V, and the Indian Diabetes Prevention Programme (IDPP) The Indian Diabetes Prevention Programme shows that lifestyle modifi cation and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1) Diabetologia 2006; 49: 289-97
167. Lindblad U, Lindberg G, Mansson NO, et al. Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY). Diabetes Obes Metab 2011; 13: 185-88
168. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, and the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-77
169. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study oforlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-61
170. Holman RR, Haff ner SM, McMurray JJ, et al, and the NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1463-76
171. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic ß-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51: 2796-803
172. Knowler WC, Hamman RF, Edelstein SL, et al, and the Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005; 54: 1150-56
173. Gerstein HC, Yusuf S, Bosch J, et al, and the DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Drug) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-105
174. DeFronzo RA, Tripathy D, Schwenke DC, et al, for the ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364: 1104-15
175. Zinman B, Harris SB, Neuman J, et al. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet 2010; 376: 103-11
176. Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008; 371: 1783-89
177. Knowler WC, Fowler SE, Hamman RF, et al, and the Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374: 1677-86
178. Lindstrom J, Ilanne-Parikka P, Peltonen M, et al, and the Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368: 1673-79
179. Gong Q, Gregg EW, Wang J, et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study Diabetologia 2011; 54: 300-07
180. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE, and the Diabetes Prevention Program Research Group Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012; 379: 2243-51
181. Scheen AJ. Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes? Diabetes Metab 2007; 33: 3-12
182. Fradkin JE, Roberts BT, Rodgers GP. What's preventing us from preventing type 2 diabetes? N Engl J Med 2012; 367: 1177-79
183. TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and ß-cell function in TODAY. Diabetes Care 2013; 36: 1749-57
184. Zeitler P, Hirst K, Pyle L, et al, and the TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012; 366: 2247-56
185. TODAY Study Group. Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care 2013; 36: 1758-64
186. TODAY Study Group. Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care 2013; 36: 1735-41
187. TODAY Study Group. Retinopathy in youth with type 2 diabetes participating in the TODAY clinical trial. Diabetes Care 2013; 36: 1772-74
188. Nathan DM, Cleary PA, Backlund JY, et al, and the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-53
189. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 2008; 359: 1577-89
190. Gerstein HC, Ambrosius WT, Danis R, et al, and the ACCORD Study Group. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care 2013; 36: 1266-71
191. Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med 2008; 359: 1092-95
192. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: I. Design, methods and baseline results Diabetes 1970; 19 (suppl 2): 747-83
193. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970; 19 (suppl 2): 789-830
194. Monami M, Cremasco F, Lamanna C, et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011; 2011: 215764
195. Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011; 27 (suppl 3): 57-64
196. Nathan DM, Buse JB, Kahn SE, et al, and the GRADE Study Research Group. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE) Diabetes Care 2013; 36: 2254-61
197. Nadeau KJ, Mather KJ, Arslanian SA, et al, for the RISE Consortium. Restoring Insulin Secretion (RISE): design of studies of s-cell preservation in prediabetes and early type 2 diabetes across the lifespan. Diabetes Care (in press)
198. Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects N Engl J Med 2012; 367: 695-704
199. Sjostrom L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65
200. Sjostrom L, Narbro K, Sjostrom CD, et al, and the Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-52
201. Rubino F, Schauer PR, Kaplan LM, Cummings DE. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med 2010; 61: 393-411
202. Asmal AC, Marble A. Oral hypoglycaemic agents. An update. Drugs 1984; 28: 62-78